Tenet Fintech Group Inc. (CSE: PKK, OTC Pink: PKKFF)
Commercial Lending in China Ready to Tenet!
China’s I-Mab Biopharma inked a $548 million agreement with Genexine of South Korea to in-license China rights to Genexine’s immunoncology candidate, HyLeukin. I-Mab paid $12 million upfront and is responsible for the remainder in milestones, plus royalties on sales. HyLeukin uses Interleukin-7, a factor in the proliferation and homeostasis of T cells, to create the immunotherapy. Genexine is a prolific dealmaker with China pharmas — it is a major investor in I-Mab and has forged several deals with Tasly Pharma, also an investor in I-Mab along with C-Bridge Capital.
Source: China Biotoday
